News Boehringer/Zealand dual-acting drug causes 16.6% weight loss Boehringer/Zealand reveal first phase 3 data with dual GLP-1/glucagon weight-loss drug survodutide.
News AI in drug discovery and development: news watch Recent developments in the biopharma AI world include a big financing for Verily, and updates from Zealand, Latent Labs, Insilico, and BMS/insitro.
News Zealand hit as Roche-partnered obesity drug disappoints Shares in Zealand lost a third of their value today, after the biotech reported phase 2 data with Roche-partnered weight-loss therapy petrelintide.
News Pfizer's $2bn+ obesity bet, and other weight-loss news Pfizer licenses another GLP-1 agonist, from YaoPharma, plus clinical updates from Zealand, Structure, Ascletis, Wave, and Boehringer Ingelheim.
News Ironwood crashes down as FDA seeks new phase 3 trial Shares in Ironwood fell by a third after it revealed the FDA is insisting on a new phase 3 trial of its short bowel syndrome therapy apraglutide.
News Roche builds in obesity with $5.3bn Zealand licensing deal Roche has parted with $1.4 billion upfront to secure rights to an obesity candidate developed by Zealand Pharma.
News OpenBind unveils its first AI model for drug discovery A research consortium that aims to make the UK a leader in AI-driven drug discovery, OpenBind, has hit its first major milestone.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
